KHK7791 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Mar 8, 2021 → Aug 10, 2021
NCT ID
NCT04767581About KHK7791 + Placebo
KHK7791 + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04767581. Target conditions include Hyperphosphatemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04766398 | Phase 3 | Completed |
| NCT04767581 | Phase 3 | Completed |
| NCT03864458 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia